Curr Probl Cancer 2016 Mar - Aug
Endocrine therapy and strategies to overcome therapeutic resistance in breast cancer.   

Related Questions

OS benefit was limited to patients with endocrine sensitivity, defined as either a documented clinical benefit (CR, PR, or SD for ≥24 weeks) f...

AI+ CK4/6 inhibitor? Fulvestrant + CK4/6 inhibitor? AI + fulvestrant? AI + fulvestrant + CK4/6 inhibitor?